Print
Email
Print Edition StoriesTuesday, August 10, 2010
Startup Mercator Therapeutics maps out $2M funding round
By Rodney H. Brown
MHT's Emerging Technologies Forum: Health IT and the Cloud
MHT's Jackie Noblett: Maine becoming a hub for pet-oriented biotechs
Biotech startup Mercator Therapeutics Inc. has raised $2 million in its first round of equity funding, according to federal documents.
The Wellesley-based company, founded in 2009, is very stealthy. It has no website, but according to the filing with the U.S. Securities and Exchange Commission, Mercator is led by president and CEO Christopher Guiffre, former chief business officer for Hydra Biosciences Inc. of Cambridge. Guiffre was also a senior vice president and the general counsel at Lexington’s Cubist Pharmaceuticals Inc., which in October of 2009 invested $15 million in Hydra.
None of the eight participants in the funding round were specifically identified in the SEC document.
Listed in the filing as a director of Mercator is life sciences veteran Mark Leuchtenberger. Currently serving as president and CEO of Conn.-based Rib-X Pharmaceuticals Inc., Leuchtenberger previously led Targanta Therapeutics Inc. to a successful IPO in 2007 and its acquisition by The Medicines Company in 2009. Prior to Targanta, he was president and CEO of Therion Biologics Corp. and previously had spent 12 years at Biogen Inc. (now Biogen Idec Inc.).
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
